CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it has completed patient enrollment in COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), the Company’s Phase 2b clinical trial designed to evaluate the safety and efficacy of CRx-102 in subjects with symptomatic knee osteoarthritis. The COMET-1 clinical study has been overenrolled, with 279 patients participating. CRx-102 is an oral synergistic combination drug candidate in development for immuno-inflammatory diseases, including osteoarthritis and rheumatoid arthritis.
